Yusa K, Tamura J, Waki A, Tsuruo T
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Biochim Biophys Acta. 1995 Nov 30;1269(3):260-6. doi: 10.1016/0167-4889(95)00128-5.
We isolated revertant and resistant clones from multidrug-resistant K562/ADM cells and evaluated the expression of P-glycoprotein and the DNA copy number of MDR1. The 9 revertant clones contained 2- to 26-fold DNA copies of MDR1; however, they expressed an extensively decreased P-glycoprotein compared with K562/ADM, while the 10 multidrug-resistant clones contained 4- to 48-fold DNA copies, and the expression level of P-glycoprotein was dependent on the copy number of MDR1 DNA. The decreased expression of P-glycoprotein in the revertants was not due only to the loss of the copy number of MDR1 DNA. To elucidate the mechanism of P-glycoprotein expression decrease in the revertants, a revertant clone (R1-5) was fused with a multidrug-resistant clone (A2-1) or with a drug-sensitive clone isolated from K562. Compared with K562 clone, the A2-1 contained 32-fold MDR1 DNA copies and showed 131-fold resistance to Adriamycin. The revertant clone R1-5 contained 26-fold MDR1 DNA copies but expressed only 5% the P-glycoprotein of A2-1 cells and showed only 2-fold resistance to Adriamycin. For selection of intraspecific hybrids, a neomycin-resistant or a blasticidin S-resistant gene was introduced into clones by electroporation of pSV2neo or pSV2bsr. The introduction of these resistant genes did not alter the copy number or expression of MDR1 in the clones. Hybrid cells between R1-5bsr and A2-1neo were found to express 136 +/- 15% of the P-glycoprotein of A2-1 cells evaluated by quantitive flow cytometry. These hybrid cells contained 41- to 48-fold MDR1 copies and showed the multidrug-resistant phenotype, such as decrease of rhodamine123 accumulation and 120- to 210-fold resistance to Adriamycin (compared with K562), indicating that the 'silent' MDR1 genes in the revertant clone R1-5 were activated by cell fusion with an MDR clone. R1-5bsr x K562neo hybrids were found to contain 8- to 11-fold MDR1 copies and there was no increase in P-glycoprotein expression as compared with R1-5.
我们从多药耐药的K562/ADM细胞中分离出回复突变体和耐药克隆,并评估了P-糖蛋白的表达及MDR1的DNA拷贝数。9个回复突变体克隆含有2至26倍MDR1的DNA拷贝;然而,与K562/ADM相比,它们的P-糖蛋白表达大幅降低,而10个多药耐药克隆含有4至48倍的DNA拷贝,且P-糖蛋白的表达水平取决于MDR1 DNA的拷贝数。回复突变体中P-糖蛋白表达的降低并非仅仅由于MDR1 DNA拷贝数的丢失。为阐明回复突变体中P-糖蛋白表达降低的机制,将一个回复突变体克隆(R1-5)与一个多药耐药克隆(A2-1)或从K562分离出的一个药物敏感克隆进行融合。与K562克隆相比,A2-1含有32倍的MDR1 DNA拷贝,对阿霉素显示出131倍的抗性。回复突变体克隆R1-5含有26倍的MDR1 DNA拷贝,但仅表达A2-1细胞P-糖蛋白的5%,对阿霉素仅显示出2倍的抗性。为筛选种内杂种,通过电穿孔导入pSV2neo或pSV2bsr将新霉素抗性或杀稻瘟菌素S抗性基因导入克隆。这些抗性基因的导入并未改变克隆中MDR1的拷贝数或表达。通过定量流式细胞术评估发现,R1-5bsr和A2-1neo之间的杂种细胞表达A2-1细胞P-糖蛋白的136±15%。这些杂种细胞含有41至48倍的MDR1拷贝,并表现出多药耐药表型,如罗丹明123摄取减少以及对阿霉素有120至210倍的抗性(与K562相比),表明回复突变体克隆R1-5中“沉默”的MDR1基因通过与一个MDR克隆细胞融合而被激活。发现R1-5bsr×K562neo杂种含有8至11倍的MDR1拷贝,与R1-5相比,P-糖蛋白表达没有增加。